Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
WALTHAM, Mass., March 01, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Barclays Global Healthcare Conference at the Loews Hotel in Miami, Florida on Wednesday, March 14, 2018. Lonnie Moulder, CEO of TESARO, will participate in an analyst-led moderated Q&A from 2:35 to 3:00 PM ET and in meetings with investors.
- The Morgan Stanley Healthcare Corporate Access Day at the Boston Harbor Hotel in Boston, Massachusetts on Tuesday, March 20, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
A live webcast of the presentation at the Barclays conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
1.781.325.1116
[email protected]
